Better diagnosis for hypophosphatasia in rheumatology patients
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism clinical trials.
This study aims to find better ways to diagnose hypophosphatasia (HPP) in adults who see a rheumatologist. If your doctor suspects HPP and you have a low ALP blood test, you may be able to help researchers develop a screening tool.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your rheumatologist needs to suspect you might have hypophosphatasia (HPP).
- You must have a blood test result showing a low level of alkaline phosphatase (ALP) – a normal enzyme that can be low in HPP.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a long-term observational study (not a drug trial) that follows adults with signs of hypophosphatasia, a condition linked to very low alkaline phosphatase levels and sometimes a gene change. It aims to better understand the condition over time and how symptoms look and progress.
This study follows people who already have hypophosphatasia (HPP) to better understand how the condition changes over time. It may help doctors recognize patterns and improve care, even if you are not receiving a new treatment.
This study looks at how changes in the ALPL gene affect the natural course of hypophosphatasia (HPP). It aims to learn more about the condition in people who have not received enzyme replacement therapy.
This study follows children with hypophosphatasia (HPP) to better understand how they do while receiving asfotase alfa. It may help improve care for families living with pediatric-onset HPP.
This trial tests a new medicine called ALE1 for hypophosphatasia (HPP), a rare bone condition. It first checks safety in healthy volunteers, then tests if the medicine helps people with HPP.
This registry collects information about people diagnosed with X-linked hypophosphatemia (XLH). It helps researchers better understand the condition and may support future studies by tracking patients over time.
Hear when a new Hypophosphatasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.